加载中
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
前收盘价
US$3.75
−US$0.02 · -0.53%
盘前
US$3.67
−US$0.08 · -2.13%
10月13日 8:11 ET
盘中时间采用ET。市场数据可能有所延迟。
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$3.75
52周区间
当前US$3.75
盘中时间采用ET。市场数据可能有所延迟。
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$3.75
52周区间
当前US$3.75
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 8000万 USD | 280.5万 USD | 634.2万 USD | 1916.3万 USD |
| 销货成本 | 139万 USD | 6338.6万 USD | 7180.1万 USD | 7678.2万 USD | 6970.1万 USD |
| 毛利 | −139万 USD | 1661.4万 USD | −6899.6万 USD | −7044万 USD | −5053.8万 USD |
| 研究与开发 | 5610.3万 USD | 6338.6万 USD | 7180.1万 USD | 7678.2万 USD | 6970.1万 USD |
| 销售、一般及管理费用 | 2866.6万 USD | 3644.8万 USD | 4166.8万 USD | 4169.4万 USD | 3051.6万 USD |
| 营业费用 | 8337.9万 USD | 3851.1万 USD | 4166.8万 USD | 4212.1万 USD | 3051.6万 USD |
| 利息收入 | — | — | — | — | 20.7万 USD |
| 折旧和摊销 | 139万 USD | 159.3万 USD | 217.2万 USD | 241.4万 USD | 251.5万 USD |
| 营业利润 | −8476.9万 USD | −2189.7万 USD | −1.11亿 USD | −1.13亿 USD | −8105.4万 USD |
| 净利润 | −7488万 USD | −972.5万 USD | −9733.5万 USD | −1.1亿 USD | −8084.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$3.60
下跌空间 4.00%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI806.92万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM664.96万0.01%787.4亿 USD0.19%US$277.9-0.37%
iShares Biotechnology ETFIBB216.18万0.02%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Extended Market ETFVXF215.26万0.00%954亿 USD0.05%US$233.52-0.63%
Fidelity Enhanced Small Cap ETFFESM192.85万0.03%64.1亿 USD0.28%US$45.24-0.48%
Vanguard Russell 2000 ETFVTWO132.27万0.01%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA122.4万0.01%217.13亿 USD0.03%US$32.66-0.40%
iShares Micro-Cap ETFIWC80.15万0.06%13.17亿 USD0.60%US$181.66-0.73%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
